Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeVKTXViking Therapeutics$24.59+2.8%$29.94$23.27▼$81.86$2.76B0.93.89 million shs731,778 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceVKTXViking Therapeutics-0.99%-14.55%-17.18%-40.58%-69.92%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationVKTXViking Therapeutics4.2271 of 5 stars4.51.00.04.72.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceVKTXViking Therapeutics 3.00Buy$95.18287.09% UpsideCurrent Analyst Ratings BreakdownLatest VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.003/11/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.002/13/2025VKTXViking TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$102.002/7/2025VKTXViking TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $70.002/7/2025VKTXViking TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $96.002/7/2025VKTXViking TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$38.002/6/2025VKTXViking TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$122.00 ➝ $125.002/6/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.002/6/2025VKTXViking TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$74.00 ➝ $71.001/17/2025VKTXViking TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$102.00 ➝ $102.00(Data available from 4/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookVKTXViking TherapeuticsN/AN/AN/AN/A$3.48 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateVKTXViking Therapeutics-$109.96M-$1.00N/AN/AN/AN/A-11.93%-11.57%4/23/2025 (Estimated)Latest VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/23/2025N/AVKTXViking Therapeutics-$0.34N/AN/AN/AN/AN/A2/5/2025Q4 2024VKTXViking Therapeutics-$0.27-$0.32-$0.05-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioVKTXViking TherapeuticsN/A36.4736.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipVKTXViking Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableVKTXViking Therapeutics20112.25 million106.20 millionOptionableVKTX HeadlinesRecent News About These CompaniesViking Therapeutics (NASDAQ:VKTX) Sets New 12-Month Low - Time to Sell?April 2 at 5:43 AM | marketbeat.comClearbridge Investments LLC Sells 98,456 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)April 2 at 4:55 AM | marketbeat.comViking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?April 2 at 4:40 AM | fool.comViking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by DnB Asset Management ASApril 2 at 4:27 AM | marketbeat.comAmerican Century Companies Inc. Increases Stock Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)April 2 at 3:34 AM | marketbeat.comViking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You TradeApril 1 at 6:55 PM | zacks.comKLP Kapitalforvaltning AS Buys New Stake in Viking Therapeutics, Inc. (NASDAQ:VKTX)April 1 at 3:49 AM | marketbeat.comViking Therapeutics Sees Unusually High Options Volume (NASDAQ:VKTX)April 1 at 2:25 AM | americanbankingnews.comViking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past MonthMarch 31 at 5:40 PM | uk.finance.yahoo.comTraders Purchase High Volume of Call Options on Viking Therapeutics (NASDAQ:VKTX)March 31 at 5:13 PM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Hits New 1-Year Low - Should You Sell?March 31 at 12:22 PM | marketbeat.comWhich Healthcare Stock Is the Best Buy Right Now?March 31 at 7:15 AM | marketbeat.comPictet Asset Management Holding SA Reduces Holdings in Viking Therapeutics, Inc. (NASDAQ:VKTX)March 30 at 4:54 AM | marketbeat.comBlair William & Co. IL Buys 44,915 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)March 30 at 4:37 AM | marketbeat.com3VKTX : A Closer Look at Viking Therapeutics's Options Market DynamicsMarch 28, 2025 | benzinga.comBrokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetMarch 27, 2025 | zacks.comVKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss DrugMarch 27, 2025 | zacks.comBIT Capital GmbH Has $5.01 Million Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)March 27, 2025 | marketbeat.comViking Therapeutics completes enrollment in Phase 2 trial of VK2735March 27, 2025 | markets.businessinsider.comViking Therapeutics (NASDAQ:VKTX) Trading Down 5% - Should You Sell?March 26, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)March 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?By Jea Yu | March 18, 2025View Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?Which Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?VKTX Company DescriptionsViking Therapeutics NASDAQ:VKTX$24.61 +0.70 (+2.94%) As of 10:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Apple Stock and 1 Significant Risk Salesforce: The Most Resilient Software Stock for Downturns D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Boeing Stock Upgraded After Beating Lockheed for Jet Deal Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
